Going Too Far Is the Same as Falling Short†: Kinesin-3 Family Members in Hereditary Spastic Paraplegia

AbstractSpastic paraplegia (SPG) type 4 is an autosomal dominant SPG caused by functional variants in the SPAST gene. We examined a Japanese family with three autosomal dominant SPG patients. These patients presented with typical symptoms of SPG, such as spasticity of the lower limbs. We identified a rare nonsynonymous variant, NM_014946.4:c.1252G>A [p.Glu418Lys], in all three family members. This variant has previously been reported in a Russian SPG family as a “likely pathogenic” variant.5 Ascertainment of additional patients carrying this variant in an unrelated Japanese SPG family further supports its pathogenicity. Molecular diagnosis of SPG4 in this family with hereditary spastic paraplegia is confirmed.

Download Full-text

Case report on novel mutation in SPAST gene in Polish family with spastic paraplegia

BMC Neurology ◽

10.1186/s12883-019-1561-6 ◽

2019 ◽

Vol 19 (1) ◽

Author(s):

Aleksandra Klimkowicz-Mrowiec ◽

Anna Dziubek ◽

Malgorzata Sado ◽

Marek Karpiński ◽

Agnieszka Gorzkowska

Keyword(s):

Case Report ◽

Genetic Testing ◽

Family History ◽

Lower Limb ◽

Hereditary Spastic Paraplegia ◽

Novel Mutation ◽

Family Members ◽

Spastic Paraplegia ◽

Limb Spasticity ◽

Lower Limb Spasticity

Abstract Background Hereditary spastic paraplegia is a large group of degenerative, neurological disorders characterized by progressive lower limb spasticity and weakness. The disease was investigated precisely but still clinicians often make incorrect or late diagnosis. Our aim was to investigate the genetic background and clinical phenotype of spastic paraplegia in large Polish family. Case presentation A 37 years old woman presented with 4-year history of walking difficulties. On neurological examination, she had signs of upper motor lesion in lower extremities. She denied sphincter dysfunction and her cognition was normal. Her family history was positive for individuals with gait problems. The initial diagnosis was familial spastic paraplegia. Genetic testing identified a novel mutation in SPAST gene. All available family members were examined and had genetic testing. The same mutation in SPAST gene was identified in other affected family members. All patients caring the mutation presented with different phenotypes. Conclusion This study presents a family with spastic paraplegia due to a novel mutation c.1390G›T(p.Glu464Term) in SPAST gene. Affected individuals showed a range of phenotypes that varied in their severity. This case report demonstrates, the signs of hereditary spastic paraplegia can be often misdiagnosed with other diseases. Therefore genetic testing should always be considered in patients with lower limb spasticity and positive family history in order to help to establish the correct diagnosis.

Download Full-text

Autosomal recessive hereditary spastic paraplegia: a rare case of a family with phenotypic variation

Current Pharmacogenomics and Personalized Medicine ◽

10.2174/1875692117999201211142908 ◽

2020 ◽

Vol 17 ◽

Author(s):

Mor Saban ◽

Tal Shachar

Keyword(s):

Genetic Testing ◽

Phenotypic Variation ◽

Hereditary Spastic Paraplegia ◽

Neurodegenerative Disorder ◽

Age Of Onset ◽

Treatment Options ◽

Family Members ◽

Complex Form ◽

Single Family ◽

Spastic Paraplegia

Background: Hereditary spastic paraplegia is a neurodegenerative disorder with a pure and complex form. More than 50 genetic types are currently known, with different ages of onset for characteristic symptoms. Data regarding hereditary spastic paraplegia remain scarce, and the rare subtype of spastic paraplegia type 5 is no exception. Objective: This report presents data regarding the case of a single family, from the city of Djerba, with five individuals affected with hereditary spastic paraplegia, the largest number of spastic paraplegia type 5 mutated family members so far reported in current literature. Methods: To emphasize the importance of genetic testing, we retrospectively reviewed a familial confirmed case of hereditary spastic paraplegia. Clinical features of family members were described. Results: The family presents a large phenotypic variation that in part differs from the known phenotypic presentations. Age of onset and clinical manifestation showed interfamilial variations. The alteration found in CYP7B1 (c.1081C>T; p.R361*) may help emphasize the importance of genetic testing and the much-needed treatment options already in use in current neurological practice. Conclusion: The understanding of the molecular pathways of hereditary spastic paraplegia, together with the establishment of disease biomarkers, will hopefully lead to better, and more personalized treatment.

Download Full-text

Two novel truncating variants in UBAP1 are responsible for hereditary spastic paraplegia

PLoS ONE ◽

10.1371/journal.pone.0253871 ◽

2021 ◽

Vol 16 (6) ◽

pp. e0253871

Author(s):

Xinchao Bian ◽

Guangying Cheng ◽

Xinbo Sun ◽

Hongkun Liu ◽

Xiangmao Zhang ◽

...

Keyword(s):

Neurite Outgrowth ◽

Neurodegenerative Disorders ◽

Hereditary Spastic Paraplegia ◽

Family Members ◽

Pure Form ◽

Dependent Manner ◽

Spastic Paraplegia ◽

Complex Disorders ◽

Hereditary Spastic Paraplegias ◽

Novel Protein

Hereditary spastic paraplegias (HSPs) are a group of rare neurodegenerative disorders. HSPs are complex disorders and are clinically and genetically heterogeneous. To date, more than 80 genes or genetic loci have been reported to be responsible for HSPs in a Mendelian-dependent manner. Most recently, ubiquitin-associated protein 1 (UBAP1) has been recognized to be involved in HSP. Here, we identified novel protein truncating variants in two families with pure form of HSP. A novel deletion (c.468_469delTG) in the UBAP1 gene was found in the first family, whereas a nonsense variant (c.512T>G) was ascertained in the second family. The variants were confirmed in all patients but were not detected in unaffected family members. The mutations resulted in truncated proteins of UBAP1. The variants did not result in different subcellular localizations in neuro-2a cells. However, each of the two variants impaired neurite outgrowth. Taken together, our findings expand the pathogenic spectrum of UBAP1 variants in HSP.

Download Full-text